Fig. 8
From: Novel models by machine learning to predict prognosis of breast cancer brain metastases
PSM adjusted OS and BCSS of BCBM patients with surgical treatment (Stratified by molecular subtype). Kaplan–Meier (K–M) survival analysis: A OS of BCBM patients with HR + /HER2− subtype; B OS of BCBM patients with HR + /HER2 + subtype; C OS of BCBM patients with HR−/HER2 + subtype; D OS of BCBM patients with HR−/HER2− subtype; E BCSS of BCBM patients with HR + /HER2− subtype; F BCSS of BCBM patients with HR + /HER2 + subtype; G BCSS of BCBM patients with HR−/HER2 + subtype; H BCSS of BCBM patients with HR−/HER2− subtype. OS overall survival, BCSS BC-specific survival, BCBM BC brain metastases, HR ±  hormone receptor positive/negative, HER2 ±  human epidermal growth factor receptor 2 positive/negative, PSM propensity score matching, HR hazard ratio, CI confidence interval